Why were breast cancer survivors told to avoid soy?
The old concern was based on a simple idea: soy contains isoflavones, which are plant compounds that can weakly mimic estrogen in the body. Since many breast cancers are fueled by estrogen, doctors worried that eating soy might stimulate tumor growth or interfere with anti-estrogen treatments like tamoxifen. This led to widespread advice for survivors to avoid soy entirely.
But that theory has been overturned by large-scale human studies. A 2023 meta-analysis of 32 observational studies found that soy isoflavone intake was actually associated with a 26% lower risk of breast cancer recurrence (hazard ratio 0.74, 95% CI 0.60-0.92) [2]. This protective effect held true even for women with estrogen receptor-positive (ER+) breast cancer, the very group that was thought to be most at risk [2]. The evidence is now clear: moderate soy consumption does not harm breast cancer survivors and may help prevent recurrence.
How much soy is safe, and what form should I eat?
The key is moderation — and the type of soy matters. The 2023 meta-analysis found the greatest reduction in recurrence risk at about 60 mg of isoflavones per day, which is roughly equivalent to 2-3 servings of traditional soy foods like tofu, tempeh, edamame, or soy milk [2]. For mortality outcomes, the benefit was seen at slightly lower intakes of 20-40 mg/day [2]. These amounts are typical of Asian diets, where soy is a staple and breast cancer rates are lower.
Importantly, the evidence supports whole soy foods, not concentrated supplements. A 2021 study of 1,460 Chinese breast cancer survivors found that moderate soy isoflavone intake (roughly the third quartile of intake) was associated with a 64% reduction in breast cancer-specific mortality (HR 0.36, 95% CI 0.16-0.82) and a 66% reduction in all-cause mortality (HR 0.34, 95% CI 0.16-0.74) compared to the lowest intake [3]. The benefit was especially clear in women taking tamoxifen and those with triple-negative breast cancer [3]. However, a 2016 study found that very high soy intake (≥62.64 mg isoflavones/day) was linked to lower bone density in breast cancer survivors, particularly in early menopause [4]. This suggests that more is not better — stick to moderate, food-based amounts.
Does soy interfere with tamoxifen or other breast cancer treatments?
No — in fact, the evidence suggests the opposite. A 2009 study of 1,954 breast cancer survivors found that among postmenopausal women taking tamoxifen, those with the highest intake of the soy isoflavone daidzein had about a 60% reduction in recurrence risk compared to those with the lowest intake (HR 0.48, 95% CI 0.21-0.79) [5]. The study concluded that soy isoflavones 'appear not to interfere with tamoxifen efficacy' [5].
This finding has been reinforced by more recent research. The 2023 meta-analysis specifically noted that soy protein and soy products were associated with a 25% reduction in breast cancer-specific mortality for ER-positive disease (HR 0.75, 95% CI 0.60-0.92) [2]. The 2021 study also found more favorable outcomes among tamoxifen users who consumed moderate soy [3]. The old fear that soy would block tamoxifen has been replaced by evidence that the two may work synergistically.
Sources used in this answer
Second Primary Breast Cancer in Young Breast Cancer Survivors
Among young breast cancer survivors (≤40 years), the 10-year risk of a second primary breast cancer was low (2.2%) for non-carriers of genetic variants, but higher (8.9%) for carriers; this study did not examine soy intake.
Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies
A 2023 meta-analysis of 32 studies found soy isoflavones associated with a 26% reduced risk of breast cancer recurrence, with greatest benefit at 60 mg/day, including in ER+ and postmenopausal survivors.
Pre-diagnosis and early post-diagnosis dietary soy isoflavone intake and survival outcomes: A prospective cohort study of early stage breast cancer survivors
In 1,460 Chinese early-stage breast cancer survivors, moderate soy isoflavone intake (third quartile) was associated with a 64% reduction in breast cancer-specific mortality and 66% reduction in all-cause mortality compared to lowest intake.
Soy isoflavone intake and bone mineral density in breast cancer survivors.
Among 1,587 breast cancer survivors, high soy isoflavone intake (≥62.64 mg/day) was associated with 1.95% lower forearm bone density and 69% higher odds of osteoporosis, especially in early menopause.
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.
In 1,954 breast cancer survivors, higher daidzein intake was associated with a 52% reduction in recurrence risk among postmenopausal tamoxifen users (HR 0.48, 95% CI 0.21-0.79), suggesting soy does not interfere with tamoxifen.